Showing results (241-250 of 247) with videos related to
Sort By:
Pageof 25
You have reached the last page of results.This site can display upto 247 results.
The Lancet. Infectious Diseases|July 20, 2023
Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trialFeng-Cai Zhu, Guo-Hua Zhong, Wei-Jin Huang, et al.Nature Communications|August 15, 2025
Immunogenicity and safety of a recombinant gE-Fc fusion protein subunit vaccine for herpes zoster in adults ≥50 years of age: a randomised, active-controlled, non-inferiority trialPeng-Fei Jin, Ya-Ru Quan, Shi-Xin Xiu, et al.National Science Review|October 22, 2021
A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2Li Zhang, Lei Cao, Xing-Su Gao, et al.The Lancet. Infectious Diseases|April 13, 2024
Immunogenicity and safety of an ORF7-deficient skin-attenuated and neuro-attenuated live vaccine for varicella: a randomised, double-blind, controlled, phase 2a trialHong-Xing Pan, Ling-Xian Qiu, Qi Liang, et al.Science Bulletin|September 24, 2023
Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6/11/16/18/31/33/45/52/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trialYue-Mei Hu, Zhao-Feng Bi, Ya Zheng, et al.Lancet (London, England)|July 24, 2020
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trialFeng-Cai Zhu, Xu-Hua Guan, Yu-Hua Li, et al.The Lancet. Infectious Diseases|June 30, 2026
Efficacy, safety, and immunogenicity of an Escherichia coli-produced nine-valent human papillomavirus vaccine: a multicentre, double-blind, randomised, controlled, phase 3 trialHong-Xing Pan, Zhao-Feng Bi, Yu-Lin Jing, et al.Pageof 25